These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 16840346)

  • 21. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8(+) T cells and antibody when expressed from modified vaccinia Ankara.
    Quinan BR; Flesch IE; Pinho TM; Coelho FM; Tscharke DC; da Fonseca FG
    Vaccine; 2014 May; 32(25):2972-9. PubMed ID: 24726244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
    Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
    J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
    Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
    Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
    Kamlangdee A; Kingstad-Bakke B; Osorio JE
    J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
    García-Arriaza J; Nájera JL; Gómez CE; Tewabe N; Sorzano CO; Calandra T; Roger T; Esteban M
    PLoS One; 2011; 6(8):e24244. PubMed ID: 21909386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
    Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
    J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
    Furumoto K; Soares L; Engleman EG; Merad M
    J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of inhibitory central nervous system-derived and stimulatory blood-derived dendritic cells suggests a dual role for granulocyte-macrophage colony-stimulating factor in central nervous system inflammation.
    Hesske L; Vincenzetti C; Heikenwalder M; Prinz M; Reith W; Fontana A; Suter T
    Brain; 2010 Jun; 133(Pt 6):1637-54. PubMed ID: 20424288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization.
    Hassett DE; Slifka MK; Zhang J; Whitton JL
    J Virol; 2000 Sep; 74(18):8286-91. PubMed ID: 10954526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting.
    Peacock JW; Nordone SK; Jackson SS; Liao HX; Letvin NL; Yafal AG; Gritz L; Mazzara GP; Haynes BF; Staats HF
    J Virol; 2004 Dec; 78(23):13163-72. PubMed ID: 15542668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.
    Chahroudi A; Garber DA; Reeves P; Liu L; Kalman D; Feinberg MB
    J Virol; 2006 Sep; 80(17):8469-81. PubMed ID: 16912297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity.
    Tenbusch M; Kuate S; Tippler B; Gerlach N; Schimmer S; Dittmer U; Uberla K
    BMC Immunol; 2008 Apr; 9():13. PubMed ID: 18405363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine strategies against Babesia bovis based on prime-boost immunizations in mice with modified vaccinia Ankara vector and recombinant proteins.
    Jaramillo Ortiz JM; Del Médico Zajac MP; Zanetti FA; Molinari MP; Gravisaco MJ; Calamante G; Wilkowsky SE
    Vaccine; 2014 Aug; 32(36):4625-32. PubMed ID: 24968152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.
    Wennier ST; Brinkmann K; Steinhäußer C; Mayländer N; Mnich C; Wielert U; Dirmeier U; Hausmann J; Chaplin P; Steigerwald R
    PLoS One; 2013; 8(8):e73511. PubMed ID: 23951355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterizing the effects of insertion of a 5.2 kb region of a VACV genome, which contains known immune evasion genes, on MVA immunogenicity.
    Ryerson MR; Shisler JL
    Virus Res; 2018 Feb; 246():55-64. PubMed ID: 29341877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.